NRI Media news & Articles | National Research Institute

March 30, 2021 – Results from a study led by Dr. Frias and the NRI team showed BIO89-100 reduces liver fat and lowers triglycerides in adults with NASH.

Weekly insulin helps patients with type 2 diabetes achieve similar blood sugar control to daily insulin

National Research Institute’s Principal Investigator and Psychiatrist, Dr. Tshekedi Dennis, Explains the Impact of COVID-19 on Mental Health

March 8, 2021 – National Research Institute Celebrates International Women’s Day 2021

February 25, 2021 – Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

February 16, 2021 – National Research Institute’s Chief Medical Officer, Dr. Mark Leibowitz, Shares His Experience as Principal Investigator for COVID-19 Vaccine Trials

January 19, 2021 – Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study

January 4, 2021 – Efﬁcacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin- Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

January 1, 2021 – Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH

December 21, 2020 – Diabetes, Liver Disease Epidemics Call for Early Detection, Monitoring, Lifestyle Changes

December 15, 2020 – National Research Institute Announces Enrollment of Volunteers for a Phase 3 Study of NVX-CoV2373 Vaccine Candidate Against COVID-19

November 24, 2020 – Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2

October 16, 2020 – NRI is Excited to Share these Clinically Relevant Results for the Efficacy and Safety of Exenatide plus Dapagliflozin for Patients with Uncontrolled Type 2 Diabetes Taking Metformin

September 22, 2020 – More Exciting News to Share from Dr. Frias and the NRI Team!

September 22, 2020 – NRI has been a proud contributor to the Pfizer COVID-19 vaccine trial!

August 13, 2020 – Important information in this Fox News article shared by National Research Institute’s Medical Director, Dr. Frias, stating that Nonalcoholic Fatty Liver Disease (NAFLD) may be among the high-risk categories for Coronavirus!

Efﬁcacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

August 6, 2020 – NATIONAL RESEARCH INSTITUTE Announces Participation and Local Enrollment for Late Stage Global Study of mRNA Vaccine Candidate Against COVID-19

July 15, 2020 – Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes

May 20, 2020 – Clinical Trials Day is a special day to recognize the people who conduct clinical trials and thank them for improving public health.

May 11, 2020 – We are excited to share some great work from Dr. Frias and the NRI team regarding Dulaglutide’s significant results tied to A1C and weight reduction in diabetes

May 7, 2020 – Topline results from HighTide Therapeutics’s HTD1801 NASH study.

May 6, 2020 – Axcella announces top-line data from AXA1125-003 clinical study on adult subjects with NAFLD

April 28, 2020 – NRI welcomes Minie Mercado, LVN, a highly seasoned research professional.

April 23, 2020 – Post Hoc Analyses Reveal Promising Results from the LixiLan‐G Trial involving Adults with type 2 Diabetes

February 12, 2020 – This is the 52-week data for the study NRI conducted. We are working on the clinical study report and look forward to the publication of the 2-year data!

January 22, 2020 – The NRI sites are so proud to have participated in this important program! Congratulations to Metacrine on the encouraging topline data!

January 2, 2020 – NRI and Dr. Frias proudly present our most recent contribution! We are so pleased to have participated in this important study and thankful for the opportunity to work together with NovoNordisk on these vital issues that impact our communities

December 23, 2019 – With great excitement, we are happy to share our first publication for 2020! We are so proud of Dr. Frias and the entire NRI research team for their valuable contribution on this important study! This is what we do!

December 8, 2019 – NRI proudly hosted our Summit colleagues this week! We are excited and honored to be partners with Summit in NASH research development!

November 29, 2019 – NRI is proud to share an important message from Dr. Frias and other experts about the importance of managing T2DM patients with high HbA1c levels

On behalf of NRI and Dr. Frias, we proudly present one of our latest publications! We are so honored to have played a role in this important study. We love what we do!

National Research Institute is proud to present Dr. Frias’ recent talk at the 25th Anniversary Conference for Taking Control of Your Diabetes in San Diego. It is with joy and passion that we share our journey in fighting Diabetes with our patients. This is what we do

Exciting news! National Research Institute (NRI) welcomes Mark T. Leibowitz, M.D. as our new Chief Medical Officer.

Very exciting news to share on behalf of Dr. Frias!

NRI Welcomes Dr. Leibowitz

On behalf of the great work at NRI and Dr. Frias, we are honored to share our involvement in this important T2DM study as presented at the European Association for the study of Diabetes in Berlin. NRI continues to lead the way in the areas of T2DM, Obesity and NAFLD through successful clinical trial performance.

NRI Awarded with the Flagship Site Award from Medpace

Exenatide once weekly improved 24-hour glucose control and reduced glycemic variability in metformin-treated patients with type 2 diabetes: a randomized, placebo-controlled trial

Sensor-enabled atorvastatin therapy lowers cholesterol, increases adherence in type 2 diabetes, hypertension

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.

NRI CLINICS ARE CURRENTLY OPEN!

COVID-19 Information